Question 1

What is Royalty Pharma?

Accepted Answer

Royalty Pharma is a Company.

Question 2

How often does Royalty Pharma appear in global news?

Accepted Answer

Tracked across 2 news events drawn from 14 articles.

Question 3

When was Royalty Pharma first tracked by Ergen?

Accepted Answer

First tracked on Jul 07, 2026.

Question 4

When was Royalty Pharma last mentioned in news?

Accepted Answer

Last active on Jul 22, 2026.

Question 5

What is Royalty Pharma's current news sentiment?

Accepted Answer

Aggregate sentiment score: 25 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Royalty Pharma in global news coverage?

Accepted Answer

Attention score of 3, derived from article volume and coverage intensity across 2 events.

Question 7

What is the most recent event involving Royalty Pharma?

Accepted Answer

Royalty Pharma acquires Neurimmune royalty (Jul 22, 2026, 7 articles).

Question 8

How did the "Royalty Pharma acquires Neurimmune royalty" event impact Royalty Pharma?

Accepted Answer

Royalty Pharma acquires a royalty interest in cliramitug, expanding its development-stage pipeline with a potential blockbuster drug.

Question 9

How did the "Teva advances TEV-408 to Phase 2b" event impact Royalty Pharma?

Accepted Answer

Royalty Pharma provides up to $500 million in R&D funding for TEV-408, sharing in potential future royalties.

Question 10

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.